Glucagon is secreted from pancreatic α-cells to activate gluconeogenesis and other pathways that raise blood glucose during hypoglycemia. Glucose-dependent regulation of glucagon secretion involves both α-cell-intrinsic mechanisms and paracrine control through insulin and somatostatin. In type-2 diabetes (T2D) inadequately high glucagon levels contribute to hyperglycemia. To understand these disease-associated changes at the cellular level, and to isolate intrinsic and paracrine effects, we analyzed glucagon granule exocytosis and membrane excitability in isolated α-cells from 56 nondiabetic (ND) and 15 T2D human donors. High resolution imaging showed that glucagon granule exocytosis had a U-shaped sensitivity to glucose, with the slowest rate around 7 mM glucose, and accelerated rates at <5 and >10 mM glucose. Exocytosis was reduced in T2D α-cells, but their glucose sensitivity remained intact and there were no changes in voltage-dependent ion currents or granule trafficking. Instead, α-cells from T2D donors were markedly insensitive to somatostatin and insulin, which rapidly inhibited exocytosis and electrical activity in ND cells. Thus, intrinsic mechanisms do not inhibit glucagon secretion at hyperglycemia, and elevated glucagon levels in human T2D reflect an insensitivity of α-cells to paracrine inhibition. , either through subtle, KATP channel-dependent depolarization of the resting membrane potential and subsequent inactivation of Na + -channels 7-10 , or as consequence of glucose-induced activation of the sarco/endoplasmic reticulum Ca 2+ -ATPase that leads to closure of store-operated channels and hyperpolarization 11, 12 . In addition, intrinsic glucose-dependent cAMP signaling may play a role 13 . However, none of these models fully explain the glucose concentration dependence of glucagon secretion, in particular in the hyperglycemic range. ȱ Glucagon secretion is also under paracrine control from neighboring β-and δ-cells, and the inhibitory effects of somatostatin [14] [15] [16] [17] [18] and GABA 24, 25 have long been recognized. Paracrine inhibition is likely to play a role at elevated glucose levels, when β-and δ-cells are active. Indeed, glucagon is secreted in pulses that are antisynchronous to pulses of insulin and somatostatin 26, 27 . This relationship is important for the postprandial suppression of glucagon secretion and is lost in type-2 diabetes and pre-diabetes 28-30 . Human and rat α-cells express the somatostatin receptor SSTR2, which leads to hyperpolarization via activation of GIRK-channels 31, 32 . At least in rats, somatostatin also inhibits the exocytosis machinery via calcineurin 32 , and inhibits α-cell exocytosis by effectively decreasing cytosolic cAMP 33, 34 . Insulin receptor signaling is required for the suppression of glucagon secretion in vivo 35 , but the precise mechanisms behind this are still debated 34, 36, 37 . Decreased sensitivity to insulin (or somatostatin) may therefore underlie the inadequate glucagon secretion in type-2 diabetes 38 .
Introduction
Glucagon is released from pancreatic α-cells and counteracts the glucose-lowering actions of insulin by stimulating gluconeogenesis and hepatic glucose output. Initially thought of only as part of the body's defense against hypoglycemia 1 , it is now clear that inadequate glucagon levels also contribute to diabetic hyperglycemia and present a challenge for diabetes management 2, 3 . Glucagon secretion is triggered by low blood glucose and suppressed at physiological glucose levels, and both α-cell intrinsic and paracrine mechanisms have been cited to explain these effects. In the intrinsic models, glucose metabolism and the generation of ATP play a central role [4] [5] [6] 
Results

Exocytosis of glucagon granules in pancreatic α-cells
Docking and exocytosis of glucagon granules at the plasma membrane was studied in dispersed islet preparations from 56 non-diabetic (ND) donors with glycated hemoglobin (HbA1c) values <6% (average 5.57±0.29%, table S1). To identify α-cells, we transduced with Pppg-EGFP and the secretory granule marker NPY-mCherry, or with Pppg-NPY-EGFP ( Fig 1A and S1A ,B) to drive expression of fluorescent proteins from the preproglucagon promoter (see methods). After culture for 26-48 h, the cells were imaged by total internal reflection (TIRF) microscopy, which selectively images fluorescence near the plasma membrane (exponential decay constant τ ~0.1 µm). The granule marker displayed a punctate staining pattern and excellent overlap with antiglucagon immunostaining ( Fig 1A) . Local application of elevated K + (75 mM, replacing Na + ) to depolarize the cells resulted in exocytosis, seen as rapid disappearance of some of the individual fluorescently labeled granules ( Fig  1B and examples in S1B,C). Most granules within the field and all granules undergoing exocytosis were essentially immobile during the experiment, suggesting that they were molecularly tethered or docked at the plasma membrane. We pooled data from ND α-cells (n=158 cells from 26 donors), which showed that 0.077±0.004 gr*µm -2 or 12±0.8% of the docked granules were released during short (40s) exposure to elevated K + (Fig 1C,  black) . Exocytosis proceeded initially at high rate (5.2*10 -3 gr*s -1 *µm -2 during the first 10 s of stimulation) and decreased later to less than 0.6*10 -3 gr*s -1 *µm -2 ; these rates are only about one-third of those observed in human β-cells 46 . Fitting with a double exponential function revealed a fast (τ=3.6±0.2 s; 39±3%; n=1325 granules) and a slow component (19.9±0.9 s; Fig 1C) . We also noticed that stimulation with K + resulted in partial depletion of docked granules ( Fig 1D) , suggesting that docking of granules to replace those lost by exocytosis is a relatively slow process. This notion was confirmed by using a double stimulation protocol ( Fig S2) . Thus, exocytosis of glucagon granules occurs with a biphasic pattern that is reminiscent of the exocytosis kinetics in other endocrine cells, suggesting the existence of granule pools with differing release probability.
Exocytosis of glucagon granules in diabetic pancreatic α-cells
During the course of this study, we also received islets from 15 donors that had been diagnosed clinically with type-2 diabetes (T2D), or whose glycated hemoglobin (HbA1c) values were above 6% (average 6.6±0.7%, table S1). When α-cells from these T2D donors were stimulated by depolarization with high K + (Fig 1B) , the rate of exocytosis was less than that observed in ND α-cells (0.057±0.006 gr*µm -2 or 75±10% of that observed in ND αcells; n=63 T2D cells from 10 donors, p=0.004; Fig 1C) . This was mostly due to a reduced proportion of the fast component (τ=2.1±0.1 s, 25±3%, n=389 granules, p=0.0008 vs ND). Since all exocytosis originated from granules that had been resident at the plasma membrane prior to stimulation, we also quantified docked granules. The density of granules in TIRF images was slightly reduced in T2D α-cells (0.57±0.02 gr*µm -2 ; n=94 T2D cells from 15 donors) compared with ND (0.61±0.008 gr*µm -2 ; n=382 ND cells from 45 donors, Fig 1D) . The finding that donor averages of K + -stimulated exocytosis and granule density correlated (Pearson r=0.39, p=0.01, 36 donors; Fig 1E) suggests that impaired granule docking underlies the reduced capacity for exocytosis, which is similar to what we have previously reported for human β-cells 46 . Interestingly, both K + -stimulated exocytosis (r=0.46, p=0.01; Fig 1F) and docked granules (r=0.31, p=0.02; Fig 1G) anti-correlated with the donor's HbA1c. The relationships are surprising given that reduced glucagon levels should lead to reduced blood glucose and HbA1c values, and suggest that the diabetic state is causal for the reduced release capacity of α-cells.
Since exocytosis in α-cells depends on Ca 2+ -influx, we used patch clamp electrophysiology to measure voltagedependent ion currents. ND or T2D cells were voltage clamped in whole-cell mode, and subjected to step depolarizations up to +70 mV from a holding potential of -70 mV ( Fig 1H) . Analysis of the resulting inward currents revealed peak Ca 2+ ( Fig 1I) and Na + -currents ( Fig 1J) that were of similar amplitude in ND and T2D cells. Half-maximal Ca 2+ -current activation was reached at -23±0.4 (ND) and -25±1.4 mV (T2D, n.s.), and half-maximal Na +current activation was at -25±0.6 (ND) and -24±0.8 mV (T2D, n.s.). We also determined depolarization evoked membrane capacitance increases as measure of exocytosis. A train of 14 depolarizations to zero mV lasting 200 ms each resulted in a total capacitance increase of 112±19 fF in ND cells and 78±19 fF in T2D cells. This corresponds to a reduction of exocytosis by 25±10 % in T2D compared with ND (p=0.1, fig 1L) , which is similar to the reduction observed by imaging granule release ( Fig 1D) . Cell size, as assessed by cell capacitance was not different in ND and T2D α-cells ( Fig 1M) .
Intrinsic regulation of glucagon secretion
To study the glucose dependence of α-cell exocytosis, we imaged granule behavior in α-cells at steady-state conditions in different glucose concentrations (1, 3, 7, 10, or 20 mM, normal K + ; Fig 2A-D) , and quantified granule exocytosis ( Fig 2B) , docked granules ( Fig 2C) and the rate of granule docking ( Fig 2D) . All three parameters displayed a bimodal relationship with the glucose concentration, with a nadir at 7 mM and a maximum at 20 mM glucose. Cells from T2D donors behaved essentially identically to cells from ND donors, with the same bimodal dose response to glucose and no significant differences at any of the tested concentrations. In both groups, the decrease in docked granules at 7 mM glucose, compared with 1 or 10 mM, was paralleled by reduced exocytosis (~50%). Since exocytosis consumes docked granules ( Fig 1C) , the finding indicates that a reduced docking rate underlies the decrease in exocytosis at 7 mM glucose. Indeed, docking rates tended to be lower at 7 mM glucose compared with 1 or 10 mM ( Fig 2D) . To study the timecourse of the glucose dependent changes in exocytosis, we altered the glucose concentration stepwise, either between 10 and 7mM ( Fig 2E) or between or between 1 and 7mM ( Fig 2F) . However, we were unable to detect changes in the exocytosis rate during the relatively short observation time, suggesting that isolated α-cells respond relatively slowly to changes in the ambient glucose concentration.
Next, we applied K + -stimulations to α-cells bathed in 1, 7, or 10 mM glucose ( Fig 2G) . This approach primarily elicits exocytosis of granules that are in a readily releasable state or "primed" for exocytosis. At all glucose concentrations, elevated K + stimulated biphasic exocytosis that was rapid, compared with the relatively slow basal exocytosis. K + -stimulated exocytosis clearly followed a biphasic timecourse and was reduced by 37±10% or 47±7% in the presence of 7 mM, compared with both 1 and 10 mM glucose, respectively. This reduction was entirely due to a slower initial phase of exocytosis, which may correspond to the immediately releasable pool of granules in β-cells 47 . In parallel, we observed a reduction in docked granules at 7 mM glucose, compared with both 1 and 10 mM ( Fig S3 A) , giving further support to the notion that the exocytotic capacity in α-cells is related to docked granules.
When α-cells from T2D donors were stimulated by depolarization with high K + , the rate of exocytosis was significantly lower than in ND α-cells (10 mM glucose, 0.069±0.009 gr*µm -2 ; n=21 cells from 4 donors, p= 0.044, Fig 2H, black) , and 1 mM condition (0.047±0.009 gr*µm -2 ; n=12 cells from 2 donors, p= 0.025, Fig 2, yellow). 7 mM glucose had similar rate on T2D cells compared to ND cells (0.039±0.009 gr*µm -2 ; n=24 cells from 3 donors, Fig 2H, blue) . The density of docked granules was similar between ND and T2D cells in all three tested glucose concentrations ( Fig S3) . These data confirm that the secretory capacity of α-cells is diminished in type-2 diabetes, an effect at the level of granule priming that is most prominent in hypoglycemic conditions.
Paracrine regulation of α-cell exocytosis
Glucagon secretion is regulated by a network of paracrine mechanisms, some of which act directly on α-cells. We therefore quantified K + -stimulated exocytosis in α-cells exposed to a panel of effectors somatostatin (SST), insulin (INS), forskolin (FSK), ϒ-aminobutyric acic (GABA), and adrenalin (ADR). As expected, the δ-cell hormone somatostatin inhibited K + -stimulated exocytosis by 65±5% (0.031±0.003 gr*µm -2 ; n=41 cells from 7 donors, Fig  3A- B, blue), compared with control (10 mM glucose; 0.089±0.007 gr*µm -2 ; n=54 cells from 11 donors, Fig 3A-B , black). Factors secreted by β-cells also affected α-cell exocytosis, with both insulin (0.04±0.003 gr*µm -2 ; n=38 cells from 6 donors, Fig 3A-B , green) and GABA reducing it by about half (0.047±0.008 gr*µm -2 ; n=16 cells from 3 donors, Fig 3A-B , brown). In contrast, adrenaline increased α-cell exocytosis by 46±27% (0.131±0.022 gr*µm -2 ; n=23 cells from 3 donors, Fig 3A-B , pink). Elevated cAMP, after exposure to forskolin, had no effect on exocytosis (0.077±0.01 gr*µm -2 ; n=30 cells from 5 donors, Fig 3A- B, purple), in contrast to previous reports 50 . None of these compounds affected the density of docked granules ( Fig 4C) . This suggests that paracrine factors modulate α-cell exocytosis independently of granule docking, likely at the level of granule priming.
In α-cells from T2D donors, exocytosis was also slowed by somatostatin (by 46±11%, 0.048±0.006 gr*µm -2 ; n=20 cells from 5 donors, Fig 3A- Next, we determined the time course of paracrine inhibition of exocytosis by rapidly applying somatostatin to α-cells ( Fig 4A, left) . Maximal inhibition of exocytosis was reached within a few seconds (mono-exponential decay constant τ=9.4±5.3s n=36 cells, 6 donors), but frequently wore off towards the end of the 1 min challenge, and could be rapidly reversed by removing somatostatin (Fig 4A, right) . Similarly, rapid effects on exocytosis were observed with with insulin ( Fig S4A) or adrenaline ( Fig S4B) . Thus, paracrine regulation of glucagon exocytosis occurs on a timescale that is consistent with the observed glucagon pulsatility 26 . Due to the small effect size, the time course of somatostatin inhibition of exocytosis could not be determined for T2D α-cells ( Fig 4B) .
Finally, we tested the effect of somatostatin on α-cell electrical activity by patch-clamp electrophysiology in the perforated patch configuration. In 10 mM glucose, electrical activity consisted of a train of action potentials as described previously 39, 51 . In ND α-cells, pulses of somatostatin (400 nM) applied to these cells caused rapid cessation of electrical activity ( Fig 4C-D) . In the example in Fig 4C, action potentials reappeared about 20 s after removal of the somatostatin. However, in many cells electrical activity returned already towards the end of the somatostatin pulse, which is apparent in the time course of the average action potential frequency ( Fig 4E) . Similar recovery during the somatostatin pulse was also seen for exocytosis ( Fig 4A) , and may reflect somatostatin receptor inactivation. In α-cells from T2D donors, the somatostatin pulse had little effect on the time course of exocytosis ( Fig 4B) or electrical activity, which is consistent with the earlier conclusion that these cells are somewhat resistant to somatostatin.
Discussion
Glucose controls glucagon secretion by intrinsic and paracrine mechanisms, but their relative significance is still debated 52 and secretory defects in type-2 diabetes are not well understood. The current work is first in using high resolution microscopy to study glucagon secretion in single, undisturbed α-cells of healthy and type-2 diabetic donors, thus isolating intrinsic from paracrine mechanisms while having full control over paracrine signaling. We show that in the absence of paracrine influence, isolated α-cells respond appropriately to hypoglycemia with an increase in glucagon granule exocytosis. This is consistent with the glucose dependence of glucagon secretion from intact islets (but not FACS sorted rat α-cells) 52, 53 , and indicates that glucagon secretion is mostly under intrinsic control in the lower glucose-concentration range. With only 2-fold difference in the exocytosis rate between minimal secretion at 7 mM and maximal secretion at 1 mM glucose, the dynamic range is small compared with β-cells. Notably, this glucose-dependent inhibition was absent in the hyperglycemic range, leading to a U-shaped response with nearly maximal exocytosis already at 10 mM glucose. This is in contrast to intact islets, in which glucagon secretion is depressed between 3 and 20 mM glucose, although even higher (non-physiological) concentrations of glucose can be stimulatory 54 . Evidently, appropriate glucagon secretion in the hyperglycemic range is lost in isolated α-cells, and paracrine inhibition is likely responsible for the physiological response in this range. We did not observe any bursts of exocytosis, as might be expected given the pulsatile glucagon secretion from intact islets. This is in line with the absence of membrane potential oscillations in single cells 55 (that we confirm here), and indicates that the islet context is required not just for intra-islet synchronization, but for oscillatory α-cell behavior as such.
Elevated glucagon is a hallmark of type-2 diabetes 56 . Despite this, both glucose-dependent and depolarization (K + )-induced exocytosis was reduced in α-cells from donors that had been diagnosed with T2D, and both exocytosis and docked granules were moderately anti-correlated with donor HbA1c values. This indicates that the exocytosis machinery in α-cells from type-2 diabetics is slightly impaired, while electrophysiological parameters (that determine electrical activity, depolarization and Ca 2+ -influx) were normal. The reason for this is unknown, but may reflect reduced expression of certain exocytosis-related proteins, as is the case in β-cells 46, 48, 49 . The reduced exocytotic capacity in T2D α-cells was most apparent in hypo-and hyperglycemic conditions, i.e. when glucose was not inhibitory (Fig 2G-H) . It is unrelated to glucose-or disease-related changes in electrical activity, because the membrane potential was clamped with elevated K + during these experiments. Since exocytosis in single α-cells is impaired rather than increased in T2D, the hyperglucagonemia in diabetic humans must be due to mechanisms that are lost in isolated cells, such as paracrine or neuronal regulation 57 . In addition, gut derived glucagon may contribute to hyperglucagonemia following oral glucose intake 58, 59 .
Exposure to insulin, somatostatin, and GABA reduced α-cell exocytosis, while adrenalin stimulated it. This is consistent with the known effects of these signaling molecules on islets, as well as systemically 52 . We show here for somatostatin that these effects are very rapid (seconds), which is consistent with the frequency of pulsatile glucagon release in vivo and from intact islets. In the absence of glucose-dependent control, paracrine inhibition by insulin and somatostatin is therefore the most likely mechanism for glucagon regulation in the hyperglycemic range. It can be speculated that the differential glucose dependence of insulin and somatostatin secretion is reflected in different target glucose ranges for their action on α-cells. Strikingly, the inhibitory effect of insulin and somatostatin on glucagon exocytosis was strongly reduced in cells from T2D donors. Together with the overall reduced exocytosis, this points to α-cell resistance to insulin and somatostatin as the main cause for inadequate glucagon secretion in type-2 diabetes, which in turn exacerbates hyperglycemia 60 . Insulin resistance is a hallmark of T2DM, and has previously been proposed as mechanism for hyperglucagonemia. For example, insulin resistance is associated with fasting glucagon levels 38 , and this inverse relationship is lost in type-2 diabetes 28 . All tested paracrine modulators affected exocytosis machinery at the priming step, rather than by increasing granule docking. This is consistent with previous findings that somatostatin inhibits exocytosis in rat α-cells through Gi-dependent depriming 32 , and reports that antagonists of SSTR2 12 or the associated G-protein cascade 12 increase glucagon secretion without altering the glucose-dependent inhibition of glucagon secretion.
Capacitance measurements indicate that glucagon granules exist in at least two states with different release probabilities, which are often referred to as the readily releasable pool of granules (RRP) and a larger reserve pool (RP) 42, 61, 62 . We show here that glucagon granules were present at the plasma membrane for extended periods before undergoing exocytosis. We interpret this as the relatively slow conversion from RP to RRP that reflects the molecular assembly of the secretory machinery at the release site, in analogy with the situation in βcells 44, 46 . Throughout the glucose range, the rate of exocytosis was nearly identical to that of granule docking (Fig 1B-D) , suggesting that docking is rate limiting for secretion. This may indeed be the case during strong (nonphysiological) stimulation, as illustrated by the finding that the glucose-dependence of depolarization-induced exocytosis followed that of granule docking. However, in physiological conditions elevated K + accelerated exocytosis about 50-fold (during the first second), which indicates a large excess in exocytotic capacity that is not triggered by normal α-cell electrical activity. A possible explanation could be that only a limited number of granules is positionally primed, i.e. located near voltage-gated Ca 2+ -granules 63 . Further theoretical work is required to understand the combination of factors affecting granule exocytosis, and the granule conversion rates provided here may be useful in this regard. Black or red asterisks indicate statistically significant differences between ND or T2D groups, respectively. (E) Plot of exocytosis frequency over time off cells exposed to 10 or 7mM glucose (blue bar).
(F) Plot of exocytosis frequency over time off cells exposed to 1 or 7mM glucose (blue bar). (E-F) Action potential frequency of α-cells from a ND (17 cells from 4 donors) or T2D (11 cells from 2 donors) donor in the presence of somatostatin (SST, 400 nM, blue bar).
Online Methods
Cells
Human pancreatic islets were obtained from the Nordic Network for Clinical Islet Transplantation Uppsala 64 or the ADI Isletcore at the University of Alberta 65 under full ethical clearance (Uppsala Regional Ethics Board 2006/348 and Alberta Human Research Ethics Board, Pro00001754) and with the donor families' written informed consent. Isolated islets were cultured free-floating in sterile dishes in CMRL 1066 culture medium containing 5.5mM glucose, 10% fetal calf serum (FCS), 2mM L-glutamine, streptomycin (100U/ml), and penicillin (100U/ml) at 37°C in an atmosphere of 5% CO2 up to two weeks. Before imaging, islets were dispersed into single cells in 2 mL cell dissociation buffer (Thermo Fisher Scientific) supplemented with trypsin (0.005%, Life Technologies) and then gentle pipetting for 30 seconds. The trypsin was then inhibited by adding four mL serumcontaining medium and centrifuged for 5 minutes at 160 g. Cells plated onto 22-mm polylysine-coated coverslips and allowed to settle overnight and infected then with different adenoviruses.
Labeling of human pancreatic α-cells and glucagon granules
To identify α-cells, we transduced dispersed human islets with adenovirus coding for enhanced green fluorescent protein (EGFP) under the control of the pre-proglucagon promoter (Shuai et al., 2016). The system takes advantage of Tet-On conditional expression in the presence of 4 μM doxycycline, to drive expression of sufficient amounts of EGFP in spite of the relatively weak pre-proglucagon promoter. The cells were simultaneously transduced with adNPY-mCherry, a well-established secretory granule marker. Alternatively, αcells granules were labeled with adenovirus coding for EGFP-tagged neuropeptide Y under control of the preproglucagon promoter (Pppg-NPY-EGFP), thus using only one construct to identify cell type and label secretory granules. For both approaches, immunostaining with an anti-glucagon antibody confirmed that over 90% of the fluorescently labeled cells were α-cells ( Fig 1A) . Confocal imaging of the immunostained cells indicated that approximately one-third of the glucagon positive cells were also labeled with Pppg-NPY-EGFP ( Fig S1A) . NPY-EGFP labeled granules had excellent overlap with punctate glucagon staining ( Fig 1A) , with 94±1% of glucagon positive granules being labeled with NPY-EGFP (37 cells, 5 donors). Thus, genetic labelling allows simple and robust identification of α-cells within pancreatic cell populations, which can be used for live-cell imaging or electrophysiology. We verified that exocytosis in the identified cells was strongly stimulated by adrenaline ( Fig   S1B-D) , which increases intracellular Ca 2+ in α-but not β-cells. The rate was slightly slower than with elevated K + (0.058±0.015 gr*µm -2 ; n=19 cells from 3 donors, Fig S1D, blue) .
Dual pulse stimulation protocol
We designed a protocol with two successive K + depolarizations (40 s each) and separated by a 2 min rest period, and quantified the recovery of exocytosis and docked granules. The second depolarization tested to what extent the remaining or newly docked granules had acquired release competence during the resting interval.
Solutions
Cells were imaged in a standard solution containing (in mM) 138 NaCl, 5.6 KCl, 1.2 MgCl2, 2.6 CaCl2, 10 D-glucose, 5 HEPES (pH 7.4 with NaOH). In Fig 2, the D-glucose concentration was varied (1 mM, 3 mM, 7 mM, 10 mM and 20 mM). Exocytosis was evoked with high K + solution (75 mM KCl equimolarly replacing NaCl in the standard solution). High K + solution was applied by computer-timed local pressure ejection from a pulled glass pipette (similar to those used for patch clamp). In Fig 3,4 , cells were imaged in standard solution (10 D-glucose) in the presence of forskolin (Fsk; 2 µM), somatostatin (SST; 400 nM), insulin (INS; 100 nM), GABA (400 nM) or adrenaline (ADR; 5 µM).
Microscopy
Cells were imaged using a custom-built lens-type total internal reflection (TIRF) microscope based on an AxioObserver Z1 with a 100x/1.45 objective (Carl Zeiss). Excitation was from two DPSS lasers at 491 and 561 nm (Cobolt) passed through a cleanup filter (zet405/488/561/640x, Chroma) and controlled with an acousto-optical tunable filter (AA-Opto). Excitation and emission light were separated using a beamsplitter (ZT405/488/561/640rpc, Chroma). The emission light was chromatically separated onto separate areas of an EMCCD camera (Roper QuantEM 512SC) using an image splitter (Optical Insights) with a cutoff at 565 nm (565dcxr, Chroma) and emission filters (ET525/50m and 600/50m, Chroma). Scaling was 160 nm per pixel.
Confocal microscopy was done with a Zeiss LSM780 using a 63/1.40 objective (Zeiss) with sequential scanning of the red (excitation 561 nm, emission 578-696 nm) and green channel (excitation 488 nm, emission 493-574 nm). Pinhole size was 0.61 mm, corresponding to 1 Airy unit. Images were acquired in 16-bit at gain settings 750 for both channels and 0.11 mm per pixel.
Image analysis
Exocytosis events were identified based on the characteristic rapid loss of the granule marker fluorescence (1-2 frames). Granule docking events were rare and defined as granules that approached the TIRF field and becoming laterally confined once they reached their maximum brightness 66 .
Docked granules were counted using the 'find maxima' function in ImageJ (http://rsbweb.nih.gov/ij). Values were normalized to each cells' contact area with the coverslip (footprint). The ΔF parameter estimates the fluorescence that is specifically localized to a granule, but subtracting a local background value (average of a 5 pixel wide annulus) from the average fluorescence value in a 3 pixel wide circle, both centered at the granule position.
Electrophysiology
Standard whole-cell voltage clamp and capacitance recordings were performed using an EPC-9 patch amplifier (HEKA Electronics, Lambrecht/Pfalz, Germany) and PatchMaster software. Voltage-dependent currents were investigated using an IV-protocol, in which the membrane was depolarized from -70 mV to +80 mV (10 mV steps) during 50 ms each. Currents were compensated for capacitive transients and linear leak using a P/4 protocol. Exocytosis was detected as changes in cell capacitance using the lock-in module of Patchmaster (30 mV peak-topeak with a frequency of 1 kHz).
Patch electrodes were made from borosilicate glass capillaries coated with Sylgard close to the tips and firepolished. The pipette resistance ranged between 2 and 4 MΩ when filled with the intracellular solution containing (in mM) 125 Cs-glutamate, 10 CsCl, 10 NaCl, 1 MgCl2, 0.05 EGTA, 3 Mg-ATP, 0.1 cAMP, and 5 HEPES, pH 7.2 adjusted using CsOH.
During the experiments, the cells were continuously superfused with an extracellular solution containing (in mM) 138 NaCl, 5.6 KCl, 1.2 MgCl2, 2.6 CaCl2, 10 D-glucose, and 5 Hepes, pH 7.4 adjusted with NaOH at a rate of 0.4 ml/min. All electrophysiological measurements were performed at 32 C. In the analysis of the measured voltage-dependent current consists of both Na + and Ca 2+ current components, were the rapid peak current (0-3 ms) represent the Na + current and the sustained current during the latter part of the depolarization reflects the Ca 2+ current. In Fig4, for membrane potential, solution was containing (in mM) 76 K2SO4, 10 KCl, 1 MgCl2and 5 HEPES, pH 7.3 adjusted with KOH.
Statistics
Data are presented as mean ± SEM unless otherwise stated. Statistical significance was tested using Students ttest and is indicated by asterisks (*p < 0.05, **p < 0.01, ***p < 0.001). Correlation was quantified as Pearson coefficient r using Excel. 
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(A) Plot of exocytosis events over time of cells exposed to 10mM glucose in the presence or absence of insulin.
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(B) Plot of exocytosis events over time of cells exposed to 10mM glucose in presence or absence of adrenaline.
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Table S1. Human donor information. 
